<DOC>
	<DOCNO>NCT02798874</DOCNO>
	<brief_summary>The 'no-reflow ' phenomenon percutaneous coronary intervention ( PCI ) patient acute ST-segment elevation myocardial infarction ( STEMI ) strong predictor short- long-term mortality . Faster antiplatelet activity increase level adenosine provide theoretical basis ticagrelor effectively prevent no-reflow PCI . We plan evaluate effect ticagrelor myocardial no-reflow PCI STEMI .</brief_summary>
	<brief_title>Effects Ticagrelor No-reflow Patients With Acute ST-segment Elevation Myocardial Infarction</brief_title>
	<detailed_description>Investigators enrol 240 patient STEMI admit Chinese PLA General Hospital September 2013 March 2015 . STEMI define typical chest pain last N30 min within previous 12 h , clear ST-segment elevation N0.1 mV ≥2 contiguous electrocardiographic lead , elevate blood level troponin T. We screen high-risk patient no-reflow risk prediction model， patient schedule undergo diagnostic cardiac angiography percutaneous coronary intervention . We randomly assign eligible patient 1:1 ratio receive either ticagrelor 180 mg clopidogrel 600 mg 30 min PCI . The primary efficacy variable prevalence no-reflow assess immediately post procedure . Secondary efficacy variable troponin T ( TnT ) , high sensitivity C-reactive protein ( hsCRP ) , interleukin-6 ( IL-6 ) , superoxide dismutase ( SOD ) , malondialdehyde ( MDA ) , endothelin-1 ( ET-1 ) , nitric oxide ( NO ) level</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>patient STEMI admit Chinese PLA General Hospital 1.unconscious presentation ; 2.had cardiogenic shock , 3.hypoglycemia , 4.diabetic ketoacidosis ; 5.had history myocardial infarction , stent thrombosis , renal insufficiency ; 6.had previously undergone coronary artery bypass surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>No-reflow</keyword>
	<keyword>Acute ST-segment elevation myocardial</keyword>
	<keyword>Reperfusion injury</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
</DOC>